Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Debt to Equity (2018 - 2023)

Historic Debt to Equity for Autolus Therapeutics (AUTL) over the last 5 years, with Q3 2023 value amounting to $0.0.

  • Autolus Therapeutics' Debt to Equity rose 15081.49% to $0.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $0.0, marking a year-over-year increase of 15081.49%. This contributed to the annual value of $0.0 for FY2022, which is 493.1% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Debt to Equity of $0.0 as of Q3 2023, which was up 15081.49% from $0.0 recorded in Q2 2023.
  • Autolus Therapeutics' Debt to Equity's 5-year high stood at $0.0 during Q3 2023, with a 5-year trough of $0.0 in Q4 2022.
  • For the 3-year period, Autolus Therapeutics' Debt to Equity averaged around $0.0, with its median value being $0.0 (2023).
  • Data for Autolus Therapeutics' Debt to Equity shows a peak YoY increase of 15081.49% (in 2023) and a maximum YoY decrease of 661.0% (in 2023) over the last 5 years.
  • Autolus Therapeutics' Debt to Equity (Quarter) stood at $0.0 in 2021, then decreased by 4.93% to $0.0 in 2022, then skyrocketed by 320.77% to $0.0 in 2023.
  • Its Debt to Equity was $0.0 in Q3 2023, compared to $0.0 in Q2 2023 and $0.0 in Q1 2023.